You are here: Home » News-IANS » Health-Medicine
Business Standard

CORE Diagnostics, Contextual Genomics to improve cancer treatment in India

IANS  |  New Delhi 

Domestic diagnostics start-up CORE Diagnostics on Tuesday partnered with Canada-based Contextual Genomics to introduce a genomic test that will improve cancer treatment in India, the company said.

The test, named "geneCORE Hotspot", detects common, clinically actionable genomic alterations in solid tumours and reports them back to the user in four weeks from histology to a report.

"We are elated to announce this partnership that allows us to bring to India one of the most significant diagnostic developments in the field of oncology and personalised medicine," said Zoya Brar, MD and Founder at CORE Diagnostics.

"geneCORE Hotspot is a major diagnostic advancement that will allow doctors to treat each patient in a unique way by identifying the mutations driving his/her disease. This test has the potential to revolutionise cancer care," Brar added.

Each cancer is different and needs an individualised treatment plan to allow patients the best chance of recovery, which can be best identified by genomic testing.

"The genomics test provides in-depth information on specific abnormalities in tumours, thereby giving physicians an insight into whether a patient will respond and benefit from a specific treatment," said Chris Wagner, President and CEO at Contextual Genomics.

The geneCORE Hotspot reports will feature a detailed clinical interpretation, with recommendations based on the mutation profile of the tumour.

The test can study over 120 carefully selected clinically actionable cancer hotspots in one panel applicable to most solid tumours.

It is a multiplex, genomic assay designed for next-generation sequencing in a CLIA certified environment, the statement said.

--IANS

rt/pgh/sac

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, August 08 2017. 18:34 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU